Augmedix, Inc. - Common Stock (AUGX)
2.3500
+0.00 (0.00%)
NASDAQ · Last Trade: Oct 28th, 2:07 PM EDT
In a monumental shift for the healthcare industry, machine learning (ML) applications are rapidly being integrated into triage systems, promising to redefine how patients are prioritized and managed. As of October 2025, these intelligent systems are moving beyond experimental phases, demonstrating significant immediate impact in alleviating emergency department (ED) overcrowding, enhancing patient safety, and optimizing [...]
Via TokenRing AI · October 27, 2025

AUGX stock results show that Augmedix missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
Via InvestorPlace · August 12, 2024
Here are three stocks to sell for investors who may want to seek out speculative opportunities in this difficult to digest market.
Via InvestorPlace · July 25, 2024

Augmedix is one of today's big winners in the market, with AUGX stock soaring on news the company will be acquired.
Via InvestorPlace · July 19, 2024

Via Benzinga · July 19, 2024
Augmedix to be acquired by Commure, Inc. for $139 million in equity. Augmedix stockholders to receive $2.35 per share. The acquisition enhances AI medical documentation solutions, boosting efficiency for healthcare providers.
Via Benzinga · July 19, 2024

Via Benzinga · July 19, 2024

Via Benzinga · May 14, 2024

Via Benzinga · May 14, 2024

Augmedix stock is down on Tuesday as investors in AUGX shares are unimpressed with the company's updated revenue outlook for 2024!
Via InvestorPlace · May 14, 2024

Via Benzinga · May 14, 2024

Via Benzinga · May 14, 2024

Pre-market stock movers are worth diving into as we check out all of the hottest news affecting shares on Tuesday morning!
Via InvestorPlace · May 14, 2024

AUGX stock results show that Augmedix beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via InvestorPlace · May 13, 2024

Via Benzinga · May 13, 2024

Although penny stocks to rebound represent one of the riskiest market categories, there could be some substance here.
Via InvestorPlace · April 19, 2024

Shares of Fusion Pharmaceuticals Inc. (NASDAQ: FUSN) rose sharply in today’s pre-market trading after the company agreed to be acquired by AstraZeneca for around $2 billion in cash.
Via Benzinga · March 19, 2024

Shares of Peraso Inc. (NASDAQ: PRSO) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter EPS results.
Via Benzinga · March 19, 2024

AUGX stock results show that Augmedix beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.
Via InvestorPlace · March 18, 2024




